睿知中国疾病研究地图
候选清单0

即将招募胃癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer

ClinicalTrials.gov 上登记的一项胃癌开放试验,由天津医科大学肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06454435,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 70 岁;性别:不限

    登记记录的入选字段

  2. Histologically confirmed gastric/gastroesophageal junction adenocarcinoma through gastroscopy.

    入选标准第 1 条

    Willing to provide blood and histological samples.

    入选标准第 21 条

  3. Treatment-naive Stage IV (clinical staging, AJCC 8th) unresectable patients, no prior antitumor therapy (including radiation, chemotherapy, targeted therapy or immunotherapy, etc.).

    入选标准第 4 条

    Locally advanced T4b.

    入选标准第 9 条

  4. Has a diagnosis of autoimmune disease within the previous 2 years (Patients with vitiligo, psoriasis, alopecia areata, or Graves' disease who do not require systemic therapy within the last 2 years, hypothyroidism requiring only thyroid hormone replacement therapy, and type I diabetes mellitus requiring only insulin replacement therapy are eligible for enrollment).

    排除标准第 15 条

    Has history of human immunodeficiency virus (HIV) infection (i.e., HIV antibody . positive); untreated acute or chronic active hepatitis B or hepatitis C infection. Patients receiving antiretroviral therapy are eligible for enrollment on an individual basis as determined by the physician with monitoring of viral copy number.

    排除标准第 18 条

  5. The Eastern Cooperative Oncology Group Performance status (ECOG PS) of 0-1.

    入选标准第 5 条

  6. Hematological status: Absolute neutrophil count (ANC) ≥1.5×10\^9/L; Platelet count (PLT) ≥100×10\^9/L; Hemoglobin (HGB) ≥9.0 g/dL.

    入选标准第 15 条

    Liver function: For patients without liver metastasis, serum total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN); ALT and AST ≤2.5×ULN. For patients with liver metastasis: TBIL ≤1.5×ULN; ALT and AST ≤5×ULN.

    入选标准第 16 条

    Renal function: Creatinine clearance (Ccr) ≥50 mL/min (calculated using the Cockcroft/Gault formula).

    入选标准第 17 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06454435,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Histologically confirmed gastric/gastroesophageal junction adenocarcinoma through gastroscopy.
  2. Ages: 18-70 Years (concluding 18 and 70 Years)
  3. Life expectancy ≥3 months.
  4. Treatment-naive Stage IV (clinical staging, AJCC 8th) unresectable patients, no prior antitumor therapy (including radiation, chemotherapy, targeted therapy or immunotherapy, etc.).
  5. The Eastern Cooperative Oncology Group Performance status (ECOG PS) of 0-1.
  6. Preoperative examinations using CT, MRI, PET-CT, etc., indicating only one unresectable factor OR peritoneal metastasis with another unresectable factor, such as:
  7. N3 lymph node metastasis, mainly referring to group 16 lymph node metastasis.
  8. Extensive or bulky lymph nodes (D2)
  9. Locally advanced T4b.
  10. Hepatic metastases (H1): ≤5 lesions with a total diameter ≤8cm.
  11. Peritoneal metastasis (CY1, P1).
  12. Ovarian metastasis (Krukenberg tumor).
  13. Physically fit for major abdominal surgery.
  14. Adequate organ and marrow function, defined as:
  15. Hematological status: Absolute neutrophil count (ANC) ≥1.5×10\^9/L; Platelet count (PLT) ≥100×10\^9/L; Hemoglobin (HGB) ≥9.0 g/dL.
  16. Liver function: For patients without liver metastasis, serum total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN); ALT and AST ≤2.5×ULN. For patients with liver metastasis: TBIL ≤1.5×ULN; ALT and AST ≤5×ULN.
  17. Renal function: Creatinine clearance (Ccr) ≥50 mL/min (calculated using the Cockcroft/Gault formula).
  18. Adequate coagulation function, defined as International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 times ULN.
  19. Voluntary participation and signed informed consent with expected good compliance and follow-up.
  20. Not involved in other clinical trials.
  21. Willing to provide blood and histological samples.
  22. No serious conditions affecting anesthesia, or surgery.
  23. No hematologic disorders affecting postoperative hemoglobin levels.

排除标准:Exclusion Criteria:

  1. Has distal metastases other than oligometastases as defined in the inclusion criteria, such as pulmonary metastases, brain metastases, bone metastases, etc.
  2. HER-2 positive patients or willing to receive Trastuzumab.
  3. Endoscopic signs of active bleeding from the lesion.
  4. Patients with moderate/large volume of ascites.
  5. Near-obstruction at the cardia or pylorus affecting feeding and gastric emptying or difficulty swallowing tablets.
  6. Concurrently suffering from other serious illnesses that are difficult to control (Severe uncontrolled recurrent infections, atrial fibrillation, angina pectoris, cardiac insufficiency, ejection fraction measurement under 50%, uncontrolled hypertension, renal insufficiency, symptomatic peripheral neuropathy, and NCI classification >II)
  7. Has already on other medications prior to enrollment or could not be assured of compliance after enrollment.
  8. Allergy to any drugs in the regimen.
  9. Women who are pregnant or breastfeeding and have childbearing potential but are not taking adequate contraceptive measures.
  10. Organ transplant recipients requiring immunosuppression.
  11. Patients without decision-making capacity or with psychiatric disorders.
  12. Systemic treatment with Chinese herbal anti-tumor or immunomodulatory drugs (including thymosin, interferons, interleukins) within 2 weeks before the first dose.
  13. Use of immunosuppressive drugs within 4 weeks before the first study treatment, excluding local steroids or physiological doses of systemic steroids.
  14. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study treatment.
  15. Has a diagnosis of autoimmune disease within the previous 2 years (Patients with vitiligo, psoriasis, alopecia areata, or Graves' disease who do not require systemic therapy within the last 2 years, hypothyroidism requiring only thyroid hormone replacement therapy, and type I diabetes mellitus requiring only insulin replacement therapy are eligible for enrollment).
  16. Known history of primary immunodeficiency.
  17. Known to have active tuberculosis.
  18. Has history of human immunodeficiency virus (HIV) infection (i.e., HIV antibody . positive); untreated acute or chronic active hepatitis B or hepatitis C infection. Patients receiving antiretroviral therapy are eligible for enrollment on an individual basis as determined by the physician with monitoring of viral copy number.
  19. Urinalysis indicating urine protein ≥2+ and 24-hour urine protein quantification >1.0g.

引自 ClinicalTrials.gov, NCT06454435, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06454435,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06454435